Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

60.0%

3 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

2 of 0 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 3
2(40.0%)
5Total
Phase 2(3)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05904626Phase 2Recruiting

Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA

Role: lead

NCT05670951Phase 3Recruiting

Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants

Role: lead

NCT02510560Phase 3Terminated

Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants

Role: lead

NCT02865122Phase 2Terminated

Safety and Efficacy Study in Infant With SBS

Role: lead

NCT01093638Phase 2Terminated

Oral Formulation of Insulin for Preterm Infants

Role: lead

All 5 trials loaded